BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 17054235)

  • 1. Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose.
    Van de Laar FA; Lucassen PL; Akkermans RP; Van de Lisdonk EH; De Grauw WJ
    Cochrane Database Syst Rev; 2006 Oct; (4):CD005061. PubMed ID: 17054235
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alpha-glucosidase inhibitors for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk of developing type 2 diabetes mellitus.
    Moelands SV; Lucassen PL; Akkermans RP; De Grauw WJ; Van de Laar FA
    Cochrane Database Syst Rev; 2018 Dec; 12(12):CD005061. PubMed ID: 30592787
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alpha-glucosidase inhibitors for type 2 diabetes mellitus.
    Van de Laar FA; Lucassen PL; Akkermans RP; Van de Lisdonk EH; Rutten GE; Van Weel C
    Cochrane Database Syst Rev; 2005 Apr; 2005(2):CD003639. PubMed ID: 15846673
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insulin secretagogues for prevention or delay of type 2 diabetes mellitus and its associated complications in persons at increased risk for the development of type 2 diabetes mellitus.
    Hemmingsen B; Sonne DP; Metzendorf MI; Richter B
    Cochrane Database Syst Rev; 2016 Oct; 10(10):CD012151. PubMed ID: 27749986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alpha-glucosidase inhibitors for patients with type 2 diabetes: results from a Cochrane systematic review and meta-analysis.
    van de Laar FA; Lucassen PL; Akkermans RP; van de Lisdonk EH; Rutten GE; van Weel C
    Diabetes Care; 2005 Jan; 28(1):154-63. PubMed ID: 15616251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of Acarbose on Incident Diabetes and Regression to Normoglycemia in People With Coronary Heart Disease and Impaired Glucose Tolerance: Insights From the ACE Trial.
    Gerstein HC; Coleman RL; Scott CAB; Xu S; Tuomilehto J; Rydén L; Holman RR;
    Diabetes Care; 2020 Sep; 43(9):2242-2247. PubMed ID: 32641379
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insulin monotherapy compared with the addition of oral glucose-lowering agents to insulin for people with type 2 diabetes already on insulin therapy and inadequate glycaemic control.
    Vos RC; van Avendonk MJ; Jansen H; Goudswaard AN; van den Donk M; Gorter K; Kerssen A; Rutten GE
    Cochrane Database Syst Rev; 2016 Sep; 9(9):CD006992. PubMed ID: 27640062
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sodium-glucose cotransporter (SGLT) 2 inhibitors for prevention or delay of type 2 diabetes mellitus and its associated complications in people at risk for the development of type 2 diabetes mellitus.
    Hemmingsen B; Krogh J; Metzendorf MI; Richter B
    Cochrane Database Syst Rev; 2016 Apr; 4(4):CD012106. PubMed ID: 27101360
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Who should benefit from the use of alpha-glucosidase inhibitors?
    Godbout A; Chiasson JL
    Curr Diab Rep; 2007 Oct; 7(5):333-9. PubMed ID: 18173965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chinese herbal medicines for people with impaired glucose tolerance or impaired fasting blood glucose.
    Grant SJ; Bensoussan A; Chang D; Kiat H; Klupp NL; Liu JP; Li X
    Cochrane Database Syst Rev; 2009 Oct; (4):CD006690. PubMed ID: 19821382
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sulphonylurea monotherapy for patients with type 2 diabetes mellitus.
    Hemmingsen B; Schroll JB; Lund SS; Wetterslev J; Gluud C; Vaag A; Sonne DP; Lundstrøm LH; Almdal T
    Cochrane Database Syst Rev; 2013 Apr; (4):CD009008. PubMed ID: 23633364
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial.
    Holman RR; Coleman RL; Chan JCN; Chiasson JL; Feng H; Ge J; Gerstein HC; Gray R; Huo Y; Lang Z; McMurray JJ; Rydén L; Schröder S; Sun Y; Theodorakis MJ; Tendera M; Tucker L; Tuomilehto J; Wei Y; Yang W; Wang D; Hu D; Pan C;
    Lancet Diabetes Endocrinol; 2017 Nov; 5(11):877-886. PubMed ID: 28917545
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is there a role for alpha-glucosidase inhibitors in the prevention of type 2 diabetes mellitus?
    Scheen AJ
    Drugs; 2003; 63(10):933-51. PubMed ID: 12699398
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of type 2 diabetes mellitus in people with intermediate hyperglycaemia.
    Richter B; Hemmingsen B; Metzendorf MI; Takwoingi Y
    Cochrane Database Syst Rev; 2018 Oct; 10(10):CD012661. PubMed ID: 30371961
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acarbose for the prevention of Type 2 diabetes, hypertension and cardiovascular disease in subjects with impaired glucose tolerance: facts and interpretations concerning the critical analysis of the STOP-NIDDM Trial data.
    Chiasson JL; Josse RG; Gomis R; Hanefeld M; Karasik A; Laakso M;
    Diabetologia; 2004 Jun; 47(6):969-75; discussion 976-7. PubMed ID: 15164169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The STOP-NIDDM Trial: an international study on the efficacy of an alpha-glucosidase inhibitor to prevent type 2 diabetes in a population with impaired glucose tolerance: rationale, design, and preliminary screening data. Study to Prevent Non-Insulin-Dependent Diabetes Mellitus.
    Chiasson JL; Gomis R; Hanefeld M; Josse RG; Karasik A; Laakso M
    Diabetes Care; 1998 Oct; 21(10):1720-5. PubMed ID: 9773737
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention.
    Unwin N; Shaw J; Zimmet P; Alberti KG
    Diabet Med; 2002 Sep; 19(9):708-23. PubMed ID: 12207806
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Network Meta-analysis of the Therapeutic Effects of Hypoglycemic Drugs and Intensive Lifestyle Modification on Impaired Glucose Tolerance.
    Zhang Y; Fu Y; Mu YM; Huang Y; Xuan J
    Clin Ther; 2021 Sep; 43(9):1524-1556. PubMed ID: 34452739
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of acarbose on cardiovascular events and new-onset diabetes in patients with coronary heart disease and impaired glucose tolerance.
    Wei Y; Xu W
    Future Cardiol; 2019 Mar; 15(2):127-133. PubMed ID: 30793928
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 18.